Stay updated with breaking news from 75886f10. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com lowered shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a strong-buy rating to a buy rating in a research note released on Tuesday. Other analysts have also recently issued research reports about the stock. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock […]
New York Life Investment Management LLC trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 16.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,289 shares of the biopharmaceutical company’s stock after selling 2,935 shares during […]
Jackson Creek Investment Advisors LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 3.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 673 shares of the biopharmaceutical company’s stock after selling 23 shares during the period. Jackson […]
Navis Wealth Advisors LLC reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 11.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,120 shares of the biopharmaceutical company’s stock after selling 150 shares during […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective hoisted by TD Cowen from $1,020.00 to $1,030.00 in a report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. A number of other analysts also recently commented on the stock. Truist Financial restated a buy rating […]